We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s adjusted earnings per share of 67 cents were in line with the Zacks Consensus Estimate. The company’s earnings beat estimates in one of the trailing four quarters and matched estimates in the other three. EW has a trailing four-quarter earnings surprise of 0.78% on average.
Q4 Estimates
The Zacks Consensus Estimate for the company’s fourth-quarter 2024 revenues is pegged at $1.36 billion, suggesting an 11.2% decline from the year-ago reported figure.
The Zacks Consensus Estimate for fourth-quarter 2024 net earnings of 55 cents per share indicates a 14.1% drop from the year-ago reported figure.
For the fourth quarter of 2024, the company projected total sales to be between $1.33 billion and $1.39 billion. It expects adjusted EPS in the band of 53 cents to 57 cents.
Edwards Lifesciences Corporation Price and EPS Surprise
The Zacks Consensus Estimate for earnings has been unchanged over the past 30 days.
Factors at Play
Similar to the last reported quarter, Edwards Lifesciences is likely to have gained from its patient-focused innovation strategy. A favorable hospitalization trend, strong global adoption of transcatheter heart valves and improved procedural volume are expected to have driven growth in the fourth quarter. However, the absence of Critical Care business operation through September is likely to have impacted the full fourth-quarter total revenues of Edwards Life Sciences.
On Sept. 3, 2024, the company announced the completion of the sell-off of the Critical Care product group to Becton, Dickinson and Company or BD, for a total value of $4.2 billion. This business recorded full-quarter revenues of $246 million in the second quarter of 2024, reflecting 7% year-over-year growth. The absence of this segment for an entire quarter is expected to have a significant impact on the company's fourth-quarter revenues on a year-over-year basis.
Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences is likely to have witnessed continued growth in procedures across the United States and worldwide. Continued strong demand for the company’s SAPIEN platform is expected to have acted as the primary growth factor. SAPIEN currently constitutes the majority of the company’s sales within the United States.
However, at the time of the third-quarter earnings release, the company talked about certain regional pressures hampering growth within the segment. In the third quarter, in Japan, slower market growth put pressure on results. This might have continued even in the fourth quarter.
For the fourth quarter, EW’s earlier-provided guidance assumed year-over-year TAVR growth below the full-year TAVR growth expectation of 5% to 7%. One of the reasons behind this was a tough year-over-year comparison. Further, the impact from hurricanes in the southeast, as well as a one-time impact from a China distributor rebate adjustment during the to-be-reported quarter are expected to have impacted the performance within TAVR.
The company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) segment’s PASCAL platform is likely to have maintained strong growth momentum in the fourth quarter globally, backed by its portfolio of differentiated therapies, positive pivotal trial results to support approvals and adoption and favorable real-world clinical outcomes. The TMTT segment’s performance is expected to have been driven by the strong adoption of the differentiated PASCAL Precision platform across the United States and Europe. Further, the company is expected to have gained business with the continued adoption of the EVOQUE tricuspid replacement system and the strong performance of the SAPIEN M3 mitral replacement system in the United States and Europe.
Our model estimates the Transcatheter Heart Valves business to report revenues of $1.10 billion, implying a 5.9% improvement from the year-ago period.
Within Surgical Structural Heart, the company is expected to have recorded strong fourth-quarter growth, banking on the penetration of its premium products across all regions.
Edwards Lifesciences is likely to have gained from strong global adoption of its premium RESILIA technology and improvement in procedural volumes. Edwards Lifesciences is expected to have seen strong global adoption of premium surgical technologies, including the MITRIS RESILIA valve, INSPIRIS and KONECT. In the fourth quarter, the company is expected to have witnessed procedure growth globally within Surgical.
Our model estimates the segment’s fourth-quarter revenues to be $264.8 million, suggesting a 6.7% rise from the year-ago quarter’s reported figure.
However, staffing shortages, which reduced hospital capacity, and choppy market conditions due to a difficult geopolitical situation are likely to have impeded the company’s growth in the quarter to be reported.
What Our Quantitative Model Predicts
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of beating estimates. This is not the case here, as you can see:
Earnings ESP: Edwards Lifesciences has an Earnings ESP of -0.03%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to post an earnings beat this quarter.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.10%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies an increase of 14.4% from the year-ago quarter reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is slated to release fourth-quarter 2024 results on Feb. 25.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.42%. The Zacks Consensus Estimate for Merit Medical’s fourth-quarter earnings implies an increase of 2.5% from the year-ago quarter figure.
Cencora (COR - Free Report) has an Earnings ESP of +0.71% and a Zacks Rank #2. The company is set to release first-quarter fiscal 2025 results on Feb. 2.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.45%. The Zacks Consensus Estimate for COR’s first-quarter EPS suggests an increase of 7% from the year-ago reported figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth
Edwards Lifesciences Corporation (EW - Free Report) is expected to report fourth-quarter 2024 results shortly.
See the Zacks Earnings Calendar to stay ahead of market-making news.
In the last reported quarter, the company’s adjusted earnings per share of 67 cents were in line with the Zacks Consensus Estimate. The company’s earnings beat estimates in one of the trailing four quarters and matched estimates in the other three. EW has a trailing four-quarter earnings surprise of 0.78% on average.
Q4 Estimates
The Zacks Consensus Estimate for the company’s fourth-quarter 2024 revenues is pegged at $1.36 billion, suggesting an 11.2% decline from the year-ago reported figure.
The Zacks Consensus Estimate for fourth-quarter 2024 net earnings of 55 cents per share indicates a 14.1% drop from the year-ago reported figure.
For the fourth quarter of 2024, the company projected total sales to be between $1.33 billion and $1.39 billion. It expects adjusted EPS in the band of 53 cents to 57 cents.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
The Zacks Consensus Estimate for earnings has been unchanged over the past 30 days.
Factors at Play
Similar to the last reported quarter, Edwards Lifesciences is likely to have gained from its patient-focused innovation strategy. A favorable hospitalization trend, strong global adoption of transcatheter heart valves and improved procedural volume are expected to have driven growth in the fourth quarter. However, the absence of Critical Care business operation through September is likely to have impacted the full fourth-quarter total revenues of Edwards Life Sciences.
On Sept. 3, 2024, the company announced the completion of the sell-off of the Critical Care product group to Becton, Dickinson and Company or BD, for a total value of $4.2 billion. This business recorded full-quarter revenues of $246 million in the second quarter of 2024, reflecting 7% year-over-year growth. The absence of this segment for an entire quarter is expected to have a significant impact on the company's fourth-quarter revenues on a year-over-year basis.
Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences is likely to have witnessed continued growth in procedures across the United States and worldwide. Continued strong demand for the company’s SAPIEN platform is expected to have acted as the primary growth factor. SAPIEN currently constitutes the majority of the company’s sales within the United States.
However, at the time of the third-quarter earnings release, the company talked about certain regional pressures hampering growth within the segment. In the third quarter, in Japan, slower market growth put pressure on results. This might have continued even in the fourth quarter.
For the fourth quarter, EW’s earlier-provided guidance assumed year-over-year TAVR growth below the full-year TAVR growth expectation of 5% to 7%. One of the reasons behind this was a tough year-over-year comparison. Further, the impact from hurricanes in the southeast, as well as a one-time impact from a China distributor rebate adjustment during the to-be-reported quarter are expected to have impacted the performance within TAVR.
The company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) segment’s PASCAL platform is likely to have maintained strong growth momentum in the fourth quarter globally, backed by its portfolio of differentiated therapies, positive pivotal trial results to support approvals and adoption and favorable real-world clinical outcomes. The TMTT segment’s performance is expected to have been driven by the strong adoption of the differentiated PASCAL Precision platform across the United States and Europe. Further, the company is expected to have gained business with the continued adoption of the EVOQUE tricuspid replacement system and the strong performance of the SAPIEN M3 mitral replacement system in the United States and Europe.
Our model estimates the Transcatheter Heart Valves business to report revenues of $1.10 billion, implying a 5.9% improvement from the year-ago period.
Within Surgical Structural Heart, the company is expected to have recorded strong fourth-quarter growth, banking on the penetration of its premium products across all regions.
Edwards Lifesciences is likely to have gained from strong global adoption of its premium RESILIA technology and improvement in procedural volumes. Edwards Lifesciences is expected to have seen strong global adoption of premium surgical technologies, including the MITRIS RESILIA valve, INSPIRIS and KONECT. In the fourth quarter, the company is expected to have witnessed procedure growth globally within Surgical.
Our model estimates the segment’s fourth-quarter revenues to be $264.8 million, suggesting a 6.7% rise from the year-ago quarter’s reported figure.
However, staffing shortages, which reduced hospital capacity, and choppy market conditions due to a difficult geopolitical situation are likely to have impeded the company’s growth in the quarter to be reported.
What Our Quantitative Model Predicts
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of beating estimates. This is not the case here, as you can see:
Earnings ESP: Edwards Lifesciences has an Earnings ESP of -0.03%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to post an earnings beat this quarter.
Masimo (MASI - Free Report) has an Earnings ESP of +4.05% and a Zacks Rank #1. The company is set to release fourth-quarter 2024 results on Feb. 25. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.10%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies an increase of 14.4% from the year-ago quarter reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is slated to release fourth-quarter 2024 results on Feb. 25.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.42%. The Zacks Consensus Estimate for Merit Medical’s fourth-quarter earnings implies an increase of 2.5% from the year-ago quarter figure.
Cencora (COR - Free Report) has an Earnings ESP of +0.71% and a Zacks Rank #2. The company is set to release first-quarter fiscal 2025 results on Feb. 2.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.45%. The Zacks Consensus Estimate for COR’s first-quarter EPS suggests an increase of 7% from the year-ago reported figure.